PharmNovo
PharmNovo is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain and is devoid of abuse potential in animal models. The unique approach of PN6047, targeting the delta opioid receptor and selectively engaging a novel biochemical mechanism of action, represents a significant advance in pain management. This combination of properties minimises the risk of common opioid-related side effects and signals a shift towards a new class of analgesics designed with patient safety and efficacy in mind.
PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research. The team comprises prominent researchers in academia and industry, and the company has an extensive international network.